Method for revaccination against epidemic parotitis in children in far north

FIELD: medicine, pediatrics.

SUBSTANCE: children who are not 6 yr old since April to July should be revaccinated with alive parotitis vaccine next year only, during the same period - since April to July. The innovation provides development of tense immunity in 6-yr-old children.

EFFECT: higher efficiency of revaccination.

12 ex

 

The invention relates to medicine, more specifically to Pediatrics. Can be used for revaccination of children mumps in the Far North.

There is a method of mass vaccination mumps through the introduction of live mumps vaccine (DRI) at the age of 6 years [New immunization schedule. Order of the Ministry of health of the Russian Federation No. 229 dated 20.06.2001,].

The known method does not take into account the peculiarities of adaptation of the immune system of the child to the changing climatic indices in the Extreme North of the polar night and polar day", a short seasons of the Northern spring, summer and autumn and long cold winters. This reduces the effectiveness of vaccination and, therefore, increases the likelihood of getting mumps. Revaccination by a known method throughout the year in the Far North provides significant material and labor costs for the work of medical teams and helicopter transport.

The objective of the invention is to increase the effectiveness of revaccination mumps and reduce material and labor costs.

The problem is solved due to the fact that the way revaccination of children living in the Far North, which consists in the introduction of live mumps vaccine on reaching the age of 6, according to the invention, form a group de is her subject revaccination, and introduce the vaccine from April to July.

The period from April to July is the most favorable for the formation of stable post-vaccination immunity that contributes to the effectiveness of revaccination.

The method is as follows. Children living in the Far North and under 6 years of age, join the group revaccination, invited to special rooms. Each of them introduced live mumps vaccine only in the period from April to July. Children who March through July not attained the age of 6 years, Vaccinium against mumps in the next year, and only from April through July.

Example 1. Konovalov, M., 6 years. Included in the group of persons to be vaccinated against mumps. Revaccination DRI in January. 1 year after revaccination protivoprostudnye antibodies was determined in titer <1:10 (seronegative).

Example 2. Lomakin P., 6 years 11 months. Revaccinate DRI in February. 1 year after revaccination protivoprostudnye antibodies was determined in titer <1:10 (seronegative).

Example 3. Tareeva I., 6 years 6 months. Revaccination DRI in March. 1 year after revaccination protivoprostudnye antibodies was determined in titer <1:10 (seronegative).

Example 4. Ivanov S., 6 years 6 months. Revaccination DRI in April. 1 year after revaccination protivoprostudnye antibodies determined is of n in titer of 1:160.

Example 5. Menshikov O., 6 years 6 months. Revaccination DRI in may. 1 year after revaccination protivoprostudnye antibodies was determined in titer of 1:640.

Example 6. Tarasova N., 6 years 6 months. Revaccination DRI in June. 1 year after revaccination protivoprostudnye antibodies was determined in titer of 1:320.

Example 7. Kochkina L., 6 years 6 months. Revaccination DRI in July. 1 year after revaccination protivoprostudnye antibodies was determined in titer of 1:160.

Example 8. Tikhonov, O., 6 years and 10 months. Revaccinate DRI in August. 1 year after revaccination protivoprostudnye antibodies was determined in titer <1:10 (seronegative).

Example 9. Korkin, I., 6 years 11 months. Revaccinate DRI in September. 1 year after revaccination protivoprostudnye antibodies was determined in titer <1:10 (seronegative).

Example 10. Razumov P., 6 years and 10 months. Revaccinate DRI in October. 1 year after revaccination protivoprostudnye antibodies was determined in titer <1:10 (seronegative).

Example 11. Konstantinov A., 6 years 9 months. Revaccinate DRI in November. 1 year after revaccination protivoprostudnye antibodies was determined in titer <1:10 (seronegative).

Example 12. Rudnev Century, 6 years 6 months. Revaccination DRI in December. 1 year after revaccination protivoprostudnye antibodies was determined in titer <1:10 (seronegative).

COI is whether the proposed method has the following advantages.

Increases the effectiveness of revaccination of children living in the Far North. In addition, 3 times reduces the period of vaccination, resulting in reduced material and labor costs.

Only in the Extreme North of the proposed method grafted DRI 621 people. Immunological survey conducted a year later, showed that the highest figures protivopolojennogo immunity is found in children, revaccinating live mumps vaccine in the period from April to July.

The method of re-vaccination of children against mumps in the Far North, which consists in the introduction of live mumps vaccine, characterized in that the children, who from April to July not attained the age of 6 years, revaccination only next year in the same period - from April to July.



 

Same patents:

FIELD: medicine, infectious diseases, psychotherapy.

SUBSTANCE: method involves antiviral therapy, immune correction with thymus hormones and interferon inductors. Since the first day the relapse symptom method involves prescription of antiox+ (1 capsule per a day) and detox+ (1 capsule, 2 times per a day) for 30 days, profluzak (20 mg, 3 times per a day for 5 days) and then in the dose 20 mg, 1 time per a day for 20 days. Derinate is prescribed topically as installation into urethra in the dose 3-5 ml or with tampon into vagina and with simultaneous prescription of microenemas in the dose 10-40 ml for 10 days. Since 10-14 day in exacerbation period in the proliferative stage of an antiherpetic immune response derinate is prescribed by intramuscular injections in the dose 5 ml, 1 time in a day, 10 injections in total number. Then since 6-th day of exacerbation and intake of profluzak psychotherapy seances are carried out. The first seance of rational psychotherapy involves explanation to a patient in available form mechanism of the disease, the necessity of prolonged treatment and motivation for treatment is enhanced by suggestion. The second psychotherapy seance involves neurolinguistic programming wherein a patient colorful and detailed description of desirable function when he imagines achievement of the desire result, and positive emotional and vegetative symptoms are notes and the conditional-reflect association is formed by tactile contact. Under psychotherapist control a patient imagines "part of person" responsible for achievement of the desire result the patient attention is accented for the desire result and arisen physiological responses are fixed by using tactile contact. Also, new behavior methods are proposed to take for a patient that are directed for achievement of the desire result - avoiding sexual contacts during exacerbation of genital herpes in one of partner and during every month hormonal cycles, avoiding stress situations, and in case of each stress situation significant for patient profluzak has to be intake in a single dose 40 mg, using a condom in sexual contact in the exacerbation period. Patient analyzes the proposed new behavior methods that help avoiding relapses, provide good state of health, promotes to recovery process of genitals recovery and selects at least three the most rationally available for him behavior methods. In the case of the positive response that is controlled by physiological symptoms the result is fixed by tactile contact. The third seance involves the suggestive psychotherapy directed for fixing the attained result. The suggestive therapy seance is carried out once per a week for 6 months. Method provides declining the treatment time, to reduce relapse frequency of genital herpes and to recover the emotional state of patient.

EFFECT: improved treatment method.

2 cl, 3 tbl, 1 ex

FIELD: veterinary virology and biotechnology.

SUBSTANCE: invention proposes the strain that possesses high antigenic and immunogenic activity. The strain is deposited in the Collection of microorganism strain FGU VGNKI at the registration name "VNIIZZH-DEP". The coronavirus strain is reproduced in transplanted cell cultures of calf kidney (MDVK, Taurus), calve coronary vessel cells and in heterologous culture of simian cells (Vero). After 3-4 days of incubation at 37°C virus is accumulated in the amount up to 108 particels/cm3 by data of electronic microscopy. The strain shows ability for reproducing in the same accumulation degree in cell culture MDVK at 34°C. The strain possesses high biological, antigenic and immunogenic activity and retains native immunobiological properties after inactivation and can be used in preparing highly sensitive and specific diagnostic, highly immunogenic, harmless and areactogenic vaccine and curative preparations.

EFFECT: valuable properties of strain, improved preparing method.

6 tbl, 4 ex

FIELD: veterinary virology, biotechnology.

SUBSTANCE: invention relates to the strain "K-58" that is deposited in the Collection FGU VGNKI at the registration number '"K-58" № 122 - DEP". The strain is reproduced in 9-11-old SPF-chicken embryos with titer value of biological activity 5.5-7.0 lg EID50/0.2 cm3. The strain is stable and harmless. Its attenuation stability is found in carrying out 5 passages in sensitive chickens. The strain shows high biological, immunogenic and antigenic activities in native state and after inactivation and useful for preparing highly specific and sensitive diagnostics and harmless live and inactivated vaccine preparations.

EFFECT: valuable veterinary properties of strain.

7 tbl, 8 ex

FIELD: veterinary virology, veterinary science, biotechnology.

SUBSTANCE: vaccine comprises antigenic material from the strain "VNIIZZH-DEP" of the cattle infectious rhinotracheitis virus reproduced in transplanted cells culture taken among transplanted cells BHK-21, MDBK and ZKG with the biological activity value at least 6.0 lg TCD50/cm3 and inactivated with aminoethylethyleneimine and also aluminum hydroxide as an adjuvant and, additionally, saponin taken in the effective ratios. The strain is deposited in the collection VGNKI at the registration code "VNIIZZH-DEP". Virus of the strain "VNIIZZH-DEP" is reproduced in transplanted cultures of cells BHK-21, MDBK and ZKG inducing cytopathic effect and virus is accumulated with the titer value 6.5-8.0 lg TCD50/cm3 for 48-96 h. Aminoethylethyleneimine is used in the concentration 0.1-0.2%, aluminum hydroxide is used as 3-4% gel in the amount 19.6-49.6 wt.-% and saponin is used as 10% aqueous solution in the amount 0.4 wt.-%. Vaccine shows high antigenic and immunogenic activity and harmless.

EFFECT: valuable properties of vaccine.

18 cl, 8 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vestibular and auditory disorders, trigeminal nerve's neuralgia and peripheral paresis of facial nerve of herpetic etiology. The method deals with introduction of an antiherpetic preparation followed by immunomodelling therapy with the use of polyoxidonium. Moreover, after treating with antiherpetic preparation before introducing polyoxidonium it is necessary to conduct additional successive therapy: with preparations of trophic action as milgamma or neuromultivit at simultaneous introduction of antioxidant, then comes intratissue injection of cerebrolysine being behind the top of mastoid process.

EFFECT: the innovation enables to decrease the quantity of relapses due to stopping the development of herpes simplex virus, restore conductivity along nervous fiber and improve endoneural circulation.

3 cl, 3 ex

Medicinal agent // 2268037

FIELD: medicine, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to using 4-chloro-2-methylphenoxyacetic acid of the formula (I)

and its pharmacologically acceptable sodium, potassium and lithium salts (mixture of these salts, or mixture of salts and 4-chloro-2-methylphenoxyacetic acid) as a medicinal agent possessing immunomodulating, anti-inflammatory and antitumor properties, and antiviral activity also. 4-Chloro-2-methylphenoxyacetic acid and its mixtures with pharmacologically acceptable alkaline metal salts possess high effectiveness and enhanced bioavailability.

EFFECT: valuable medicinal properties of medicinal agent.

9 cl, 13 ex

FIELD: chemistry of peptides, medicine.

SUBSTANCE: invention relates to preparing new peptides possessing immunomodulating, anti-proliferative, anti-tumor and antiviral activity. Invention proposes new peptides comprising up to 30 amino acid residues of the general structural formula: X1-Trp-Gly-Gln-X2 wherein X1 is taken among the following group: -His-Gly-Val-Ser-Gly-, -His-Gly-Gly-Gly-, -His-Val-Gly-Gly-, -His-Gly-Gly-Gly-Gly-, and -Gln-Gly-Gly-Gly-Gly, or absent; X2 is taken among the following group: -His-Gly-Thr-His-Gly, -Gly-Gly-Thr-His-Gly, -Pro-His-Val-Gly-Gly, -Pro-His-Gly-Gly-Gly, -Pro-His-Gly-Gly-Gly-Trp-Gly, -Gly-Gly-Gly-Thr-His-Ser, or absent.

EFFECT: valuable medicinal properties of peptides.

8 cl, 5 tbl, 5 dwg, 6 ex

FIELD: organic chemistry, medicine, virology.

SUBSTANCE: invention relates to new derivatives of piperidine of the general formula (II): or their pharmaceutically acceptable salts wherein Xa means -C(R13)2-, -C(R13)(R19)-, -C(O)-, and others; Ra means R6a-phenyl or phenyl substituted with methylsulfonyl; R1 means hydrogen atom or (C1-C6)-alkyl; R2 means R7-, R8-, R9-phenyl wherein R7-, R8 and R9 mean substituted 6-membered heteroaryl and others; R3 means R10-phenyl, pyridyl and others; R4 means hydrogen atom, (C1-C6)-alkyl, fluoro-(C1-C6)-alkyl; R6a means from 1 to 3 substitutes taken among the group involving hydrogen, halogen atom, -CF3 and CF3O-; R7 and R8 mean (C1-C6)-alkyl and others; R9 means R7, hydrogen atom, phenyl and others; R10 means (C1-C6)-alkyl, -NH2 or R12-phenyl wherein R12 means hydrogen atom, (C1-C6)-alkyl and others; R13, R14, R15 and R16 mean hydrogen atom or (C1-C6)-alkyl; R17 and R18 in common with carbon atom to which they are bound form spirane ring comprising from 3 to 6 carbon atoms; R19 means R6-phenyl wherein R6 means R6a or methylsulfonyl; R20, R21 and R22 mean hydrogen atom or (C1-C6)-alkyl; R23 means (C1-C6)-alkyl under condition that if Ra means phenyl substituted with methylsulfonyl then Xa can mean the group only. Compounds of the formula (II) possess properties of CCR5-antagonist and can be used in medicine in treatment of HIV-infection.

EFFECT: improved method for treatment, valuable medicinal properties of compounds and composition.

15 cl, 1 dwg, 12 tbl, 15 ex

FIELD: virology, veterinary science.

SUBSTANCE: invention proposes a new strain of the avian reovirus ESASS № 99011475 belonging to a new antigen class of avian reoviruses. Also, invention proposes a method for preparing such reoviruses, a vaccine comprising such reovirus, a method for its preparing and a method for control against pathological states in poultries by using such vaccine. Proposed group of inventions provides enhancing the effectiveness of vaccination of poultries against reoviruses. Invention can be used in veterinary.

EFFECT: improved preparing method, valuable properties of strain and vaccine.

9 cl, 6 dwg, 3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: one should perform the following stages: a) removal of contaminants out of plant; b) plant's reducing; c) treatment of reduced plant with laser radiation; d) suspending the mixture obtained at stage c) in water; e) maceration of suspension obtained at stage d) and f) separation of liquid developed. Composition should be obtained due to this technique. It should be applied at treating hepatitis C as an aqueous extract. It should be applied as aqueous extract as immunostimulant. Pharmaceutical preparation includes aqueous extract as an active constituent.

EFFECT: increased biological activity of the product.

43 cl, 16 ex, 1 tbl

FIELD: medicine, pediatrics.

SUBSTANCE: one should form groups in 6-yr-old children who are either going to the Far North or leaving this region. In leaving group vaccine should be introduced about 7 wk before their departure, not later, as for arriving group - about 10 wk after arrival, not earlier. One should follow these mentioned time intervals to increase efficiency of immunization against parotitis due to child's body adaptation to sharply altering climatic conditions.

EFFECT: higher efficiency of revaccination.

6 ex

FIELD: medicine, pediatrics, oncology, infectious diseases.

SUBSTANCE: invention relates to a method for carrying out vaccine prophylaxis. Invention proposes firstly to carry out vaccination and revaccination of children against measles after oncological diseases and in remission stage in 3 and more months after finishing chemotherapy and with preliminary assay of subpopulations of lymphocytes CD25+, CD95+, HLA II and serological analysis involving detection of specific anti-measles antibodies. Method involves carrying out the vaccination with live anti-measles vaccine at values of lymphocytes subpopulation above the age norm. Vaccination is not carried out at values of lymphocytes subpopulation above the age norm and in the presence of minimal protective anti-measles antibodies titers. The advantage of the invention involves the possibility for prophylaxis of severe forms of the measles infection. Invention can be used in specific prophylaxis of measles in children with oncological diseases in their anamnesis.

EFFECT: improved method for vaccination, valuable medicinal properties of method.

2 ex

The invention relates to medical Virology and Microbiology, and in particular to identification of a new strain of measles virus NovO/96 to obtain the antigen component of the diagnostic test system and the test system for the diagnosis of antibodies to measles virus

The invention relates to medicine, namely to the technology of production of microcapsules, and can be used in the pharmaceutical industry

The invention relates to medicine, in particular for Virology and biotechnology, and can be used to obtain new immunogenic and diagnostic products
The invention relates to medicine, in particular to Infectology and Allergology, and for the specific prevention of measles
The invention relates to medicine and for the creation of live culture vaccine for immunization of children

The invention relates to medicine, in particular to the production of viral vaccines in capsulated form

The invention relates to the field of biotechnology

FIELD: medicine, pediatrics, oncology, infectious diseases.

SUBSTANCE: invention relates to a method for carrying out vaccine prophylaxis. Invention proposes firstly to carry out vaccination and revaccination of children against measles after oncological diseases and in remission stage in 3 and more months after finishing chemotherapy and with preliminary assay of subpopulations of lymphocytes CD25+, CD95+, HLA II and serological analysis involving detection of specific anti-measles antibodies. Method involves carrying out the vaccination with live anti-measles vaccine at values of lymphocytes subpopulation above the age norm. Vaccination is not carried out at values of lymphocytes subpopulation above the age norm and in the presence of minimal protective anti-measles antibodies titers. The advantage of the invention involves the possibility for prophylaxis of severe forms of the measles infection. Invention can be used in specific prophylaxis of measles in children with oncological diseases in their anamnesis.

EFFECT: improved method for vaccination, valuable medicinal properties of method.

2 ex

Up!